Skip to main content

Table 1 Baseline RA patient’ characteristics

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 All patients
(n = 13)
Age, mean (SD), years; (min-max)48.23 ± 14.5, (21–67)
Female, n (%)9 (69.2%)
Disease duration, mean (SD), years; (min-max)11.46 ± 9.44; (2–36)
TCZ exposure before tapering, months (SD); (min-max)18.38 ± 7.34; (5–29)
Remission achievement delay, months (SD); (min-max)2.38 ± 2.63; (0–8)
Remission duration, months (SD); (min-max)7.53 ± 6.21; (3–24)
RF positive, n (%)7 (53.8%)
ACPA positive, n (%)7 (53.8%)
Erosive status, n (%)10 (76.9%)
Previous number of sDMARDs; (min-max)2.15 ± 0.9; (1–4)
Previous number of bDMARDs; (min-max)1.7 ± 1.18; (0–3)
Swollen joint count; (min-max)0.08 ± 0.27; (0–1)
Tender joint count; (min-max)3.14 ± 3.4; (0–10)
Hyperhemia at Doppler2 (15.4%)
Number of patients with active synovitis7 (53.8%)
Number of active synovitis
 Hands14
 Feet5
Concomitant therapy
 MTX, n (%)6 (42.9%)
 LEF, n (%)3 (21.4%)
DAS28; mean (SD); (min-max)1.65 ± 0.93; (0–2.6)
ESR, mm/h; mean (SD); (min-max)7 ± 9.12; (1–27)
CRP, mg/L, mean (SD); (min-max)2.21 ± 2.34; (0.2–7.4)
TCZ plasma level, mg/L; mean (SD); (min-max)7.35 ± 6.41; (0–16)
ADAb positivity0
  1. RA rheumatic arthritis, SD standard deviation, n number, TCZ tocilizumab, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, LEF leflunomide, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ADAb antidrug antibodies